| Drug Name |
Cangrelor |
| Drug ID |
BADD_D00348 |
| Description |
Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application. |
| Indications and Usage |
For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. |
| Marketing Status |
Prescription |
| ATC Code |
B01AC25 |
| DrugBank ID |
DB06441
|
| KEGG ID |
D03359
|
| MeSH ID |
C117446
|
| PubChem ID |
9854012
|
| TTD Drug ID |
D09QBG
|
| NDC Product Code |
10122-620; 68225-062; 50137-3312 |
| Synonyms |
cangrelor | N(6)-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic acid monoanhydride with dichloromethylenebis(phosphonic acid) | cangrelor tetrasodium | AR C69931MX | AR-C69931MX | Kengreal |
